PULMONARY SARCOMATOID CARCINOMA
Clinical trials for PULMONARY SARCOMATOID CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PULMONARY SARCOMATOID CARCINOMA trials appear
Sign up with your email to follow new studies for PULMONARY SARCOMATOID CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising combo tackles rare lung cancer in small trial
Disease control CompletedThis study tested a combination of two drugs, tislelizumab and anlotinib, in 29 people with advanced pulmonary pleomorphic carcinoma, a rare and aggressive lung cancer. The goal was to see if the combo could shrink tumors or slow the disease. Participants had stage III or IV canc…
Matched conditions: PULMONARY SARCOMATOID CARCINOMA
Phase: PHASE2 • Sponsor: Second Affiliated Hospital of Nanchang University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New combo tackles rare lung cancer
Disease control CompletedThis phase 2 trial tested a combination of the immunotherapy drug durvalumab with two chemotherapy drugs (doxorubicin and ifosfamide) in 16 people with a rare and aggressive type of lung cancer called pulmonary sarcomatoid carcinoma. The goal was to see if the combination could s…
Matched conditions: PULMONARY SARCOMATOID CARCINOMA
Phase: PHASE2 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC